Osaic Holdings’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-175
Closed -$7.16K 7640
2024
Q2
$7.16K Buy
175
+95
+119% +$3.96K ﹤0.01% 5994
2024
Q1
$3.38K Buy
80
+20
+33% +$840 ﹤0.01% 6261
2023
Q4
$2.54K Sell
60
-60
-50% -$1.72K ﹤0.01% 6450
2023
Q3
$2.62K Buy
120
+60
+100% +$1.5K ﹤0.01% 6527
2023
Q2
$1.91K Hold
60
﹤0.01% 6681
2023
Q1
$1.46K Sell
60
-5
-8% -$147 ﹤0.01% 6838
2022
Q4
$2K Hold
65
﹤0.01% 6741
2022
Q3
$2K Sell
65
-254
-80% -$7.57K ﹤0.01% 6872
2022
Q2
$9K Buy
319
+39
+14% +$1.11K ﹤0.01% 6188
2022
Q1
$10K Buy
280
+249
+803% +$7.27K ﹤0.01% 6151
2021
Q4
$1K Buy
+31
New +$1.09K ﹤0.01% 7280

Other funds holding CERE

Osaic Holdings's CERE Position: Q3 2024 in Review

Osaic Holdings sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 175 shares — an estimated $7.16K sold.

Osaic Holdings first reported a position in CERE in Q4 2021 and held it in 11 quarters. The position peaked at $10K in Q1 2022. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Osaic Holdings reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Osaic Holdings sold 175 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $7.16K.
  • Osaic Holdings first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2021 and held it in 11 quarters.
  • Osaic Holdings's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $10K in Q1 2022.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Osaic Holdings's 13F filing for Q3 2024, filed 13 Nov 2024.